Brokerages expect The Beauty Health Company (NASDAQ:SKIN – Get Rating) to announce sales of $84.84 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Beauty Health’s earnings, with the lowest sales estimate coming in at $79.50 million and the highest estimate coming in at $93.19 million. Beauty Health posted sales of $66.51 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 27.6%. The firm is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Beauty Health will report full year sales of $337.27 million for the current financial year, with estimates ranging from $333.20 million to $339.80 million. For the next fiscal year, analysts anticipate that the business will post sales of $417.75 million, with estimates ranging from $410.82 million to $425.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Beauty Health.
Beauty Health (NASDAQ:SKIN – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.05). Beauty Health had a negative net margin of 117.84% and a negative return on equity of 0.01%. The company had revenue of $75.40 million for the quarter, compared to analysts’ expectations of $68.15 million. The firm’s quarterly revenue was up 58.7% on a year-over-year basis.
A number of research firms recently weighed in on SKIN. Piper Sandler cut their target price on shares of Beauty Health from $26.00 to $24.00 in a report on Wednesday, May 11th. JPMorgan Chase & Co. began coverage on shares of Beauty Health in a report on Friday, March 11th. They issued an “overweight” rating and a $24.00 target price for the company. Canaccord Genuity Group cut their target price on shares of Beauty Health from $27.00 to $22.00 in a report on Wednesday, May 11th. Benchmark raised their target price on shares of Beauty Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Monday, March 14th. Finally, DA Davidson cut their target price on shares of Beauty Health from $35.00 to $24.00 in a report on Wednesday, May 11th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Beauty Health has a consensus rating of “Buy” and an average target price of $25.55.
Shares of SKIN opened at $12.21 on Tuesday. The company has a debt-to-equity ratio of 2.14, a current ratio of 14.25 and a quick ratio of 13.57. Beauty Health has a 1 year low of $9.94 and a 1 year high of $30.17. The company has a 50 day simple moving average of $14.85 and a two-hundred day simple moving average of $18.29. The firm has a market cap of $1.83 billion, a P/E ratio of -3.60 and a beta of 1.73.
Several large investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC bought a new stake in shares of Beauty Health during the first quarter worth $308,000. Point72 Hong Kong Ltd bought a new stake in shares of Beauty Health during the first quarter worth $189,000. Prospect Capital Advisors LLC lifted its position in shares of Beauty Health by 11.0% during the first quarter. Prospect Capital Advisors LLC now owns 256,200 shares of the company’s stock worth $4,325,000 after purchasing an additional 25,450 shares during the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of Beauty Health during the first quarter worth $2,363,000. Finally, Wellington Management Group LLP increased its stake in shares of Beauty Health by 5.5% during the first quarter. Wellington Management Group LLP now owns 2,394,159 shares of the company’s stock valued at $40,414,000 after buying an additional 125,195 shares during the period. Institutional investors and hedge funds own 72.01% of the company’s stock.
About Beauty Health (Get Rating)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with MarketBeat.com’s FREE daily email newsletter.